

Pauline Harper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2837424/publications.pdf>

Version: 2024-02-01

14
papers

902
citations

932766

10
h-index

1125271

13
g-index

14
all docs

14
docs citations

14
times ranked

911
citing authors

#	ARTICLE	IF	CITATIONS
1	RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. <i>Journal of Internal Medicine</i> , 2022, 291, 593-610.	2.7	11
2	Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. <i>Journal of Internal Medicine</i> , 2022, 291, 824-836.	2.7	26
3	A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1250-1260.	2.3	17
4	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. <i>Hepatology</i> , 2020, 71, 1546-1558.	3.6	103
5	Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2483-2487.	0.2	5
6	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2020, 382, 2289-2301.	13.9	350
7	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. <i>Genetics in Medicine</i> , 2019, 21, 2605-2613.	1.1	16
8	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2019, 380, 549-558.	13.9	194
9	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. <i>Journal of Hepatology</i> , 2016, 65, 776-783.	1.8	119
10	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. <i>Blood</i> , 2016, 128, 2318-2318.	0.6	3
11	Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria. <i>Journal of Proteomics</i> , 2015, 127, 377-385.	1.2	3
12	Management of acute intermittent porphyria. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 349-368.	0.5	22
13	Liver Transplantation in Acute Hepatic Porphyria and Erythropoietic Protoporphyrin. <i>Handbook of Porphyrin Science</i> , 2013, , 329-367.	0.3	0
14	Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 444-455.	0.3	33